Archive for December 2016
Optimization of trial design and dose selection based on the quantitative assessement of the efficacy of TAK-385
Vis P., Snelder N., Ahsman M., MacLean D. and Faessel H., Optimization of trial design and dose selection based on the quantitative assessement of the efficacy of TAK-385. WCOP, (2016).
Read MoreQSP Modelling at the heart of the action
Snelder N. and Steeg T.v., QSP Modelling at the heart of the action. ACoP, (2016).
Read MoreQuantification of the modulation of the Aβ oligomers following secretase inhibition
Maanen E.v., Steeg T.v., Savage M.J., Michener M.S., Stone J. and Danhof M., Quantification of the modulation of the Aβ oligomers following secretase inhibition; A systems pharmacology approach. Computational Hub Meeting.(2016)
Read MoreQuantification of the modulation of Aβ oligomers following secretase inhibition- A systems pharmacology approach
Maanen E.v., Steeg T.v., Kalinina J., Stone J., Michener M.S., Savage M.J., Parker E.M. and Danhof M. (2016). Quantification of the modulation of Aβ oligomers following secretase inhibition- A systems pharmacology approach. ACOP (2016)
Read MoreSystems Pharmacology Analysis of the Amyloid Cascade
van Maanen, E.M., et al., Systems Pharmacology Analysis of the Amyloid Cascade after beta-Secretase Inhibition Enables the Identification of an Abeta42 Oligomer Pool. J Pharmacol Exp Ther., 2016. 357(1): p. 205-16. doi: 10.1124/jpet.115.230565. Epub 2016 Jan 29. [Link to publication]
Read MoreThe application of mathematical modelling to the design of bispecific monoclonal antibodies
van Steeg T.J., Bergmann K.R., Dimasi N., Sachsenmeier K.F. and Agoram B., The application of mathematical modelling to the design of bispecific monoclonal antibodies, MAbs., 8(3): 585-592. doi: 510.1080/19420862.19422016.11141160. Epub 19422016 Feb 19420824., 2016. [Link to publication]
Read MorePopulation Pharmacokinetic Modeling of Tapentadol Extended Release
Huntjens D.R., Liefaard L.C., Nandy P., Drenth H.J. and Vermeulen A., Population Pharmacokinetic Modeling of Tapentadol Extended Release (ER) in Healthy Subjects and Patients with Moderate or Severe Chronic Pain, Clin Drug Investig., 36(3): 213-223. doi: 210.1007/s40261-40015-40371-x., 2016. [Link to publication]
Read MoreCharacterization and prediction of cardiovascular effects of fingolimod and siponimod
Snelder N., Ploeger B.A., Luttringer O., Rigel D.F., Webb R.L., Feldman D., Fu F., Beil M., Jin L., Stanski D.R. and Danhof M., Characterization and prediction of cardiovascular effects of fingolimod and siponimod using a systems pharmacology modelling approach, J Pharmacol Exp Ther, 1(116): 236208, 2016. [Link to publication]
Read More